Table 1.
Patient Baseline Characteristics by Randomized Treatment Arm
| No. of Patients (%) | |||
|---|---|---|---|
| Variable | Arm A (n=46) | Arm B (n=44) | |
| Age, median | 69 (range, 49–81) | 71 (range, 32–85) | |
| Gender: | Male | 29(63) | 29(66) |
| Female | 17(37) | 15(34) | |
| Race/Ethnic: | White | 40(87) | 44(100) |
| Black | 4(9) | 0 | |
| Other | 2(4) | 0 | |
| Performance Status: | 0: Active | 17(37) | 14(32) |
| 1: Ambulatory | 25(54) | 24(55) | |
| 2: In Bed < 50% | 4(9) | 4(9) | |
| 3: In Bed > 50% | 0(0) | 2(5) | |
| FAB Subtype: | RAEB | 10(22) | 18(41) |
| (Central Review, n=77) | RAEB-T | 10(22) | 4(9) |
| CMML | 9(20) | 5(11) | |
| RA,RARS,RCMD | 13(28) | 8(18) | |
| Missing | 4(9) | 9(20) | |
| FAB Subtype: | RAEB | 16(35) | 19(43) |
| (Institutional Report, n=90) | RAEB-T | 7(15) | 9(20) |
| CMML | 7(15) | 3(7) | |
| RA,RARS,RCMD | 16(35) | 13(30) | |
| IPSS Risk Group: | Low | 4(9) | 3(7) |
| (Central, n=67) | Int-1 | 19(41) | 7(16) |
| Int-2 | 11(24) | 12(27) | |
| High | 4(9) | 7(16) | |
| Missing | 8(17) | 15(34) | |
| IPSS Risk Group: | Low | 6(13) | 5(11) |
| (Institutional, n=80) | Int-1 | 20(43) | 9(20) |
| Int-2 | 10(22) | 17(39) | |
| High | 4(9) | 9(20) | |
| Missing | 6(13) | 4(9) | |
| Hematologic Parameters (median; range; interquartile range) | |||
| No. of RBC units transfused* | 6 (0–39; 2–12) | 4 (0–20; 0–8) | |
| No. of Platelet transfusion events* | 0 (0–42; 0–0) | 0 (0–17; 0–0) | |
| Hemoglobin (gm/dl) | 9 (7–12; 8–10) | 9 (6–13; 8–11) | |
| Platelets (×103 /µl) | 102 (5–456; 49–165) | 64.5 (5–420; 26–173) | |
| WBC (×103 /µl) | 3.7 (1.1–74.2; 2.3–7.8) | 2.8 (1–19.3; 1.9–6) | |
| ANC (×103 /µl)* | 1.6 (.09–43.9; 0.7–4.3) | 1.4 (.02–9.5; 0.6–3.6) | |
*
One patient had missing data on number of RBC units transfused and ANC, and 8 patients had missing data on number of platelet transfusion events.
Interquartile range includes the 25th to 75th percentiles.